Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03BBU
|
||||
| Former ID |
DNCL002419
|
||||
| Drug Name |
Lucatumumab
|
||||
| Synonyms |
HDC122
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] | Phase 2 | [521739] | ||
| Company |
Novartis Pharmaceuticals
|
||||
| CAS Number |
CAS 903512-50-5
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | Modulator | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| NF-kappa B signaling pathway | |||||
| Cell adhesion molecules (CAMs) | |||||
| T cell receptor signaling pathway | |||||
| Intestinal immune network for IgA production | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Asthma | |||||
| Autoimmune thyroid disease | |||||
| Systemic lupus erythematosus | |||||
| Allograft rejection | |||||
| Primary immunodeficiency | |||||
| Viral myocarditis | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.